Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 723735, 10 pages
http://dx.doi.org/10.1155/2015/723735
Clinical Study

A 2-Week Course of Enteral Treatment with a Very Low-Calorie Protein-Based Formula for the Management of Severe Obesity

1Clinical Nutrition Unit, A.O.R.N. “San Giuseppe Moscati”, 83100 Avellino, Italy
2Ultrasonography Unit, A.O.R.N. “San Giuseppe Moscati”, 83100 Avellino, Italy
3Liver Unit, A.O.R.N. “San Giuseppe Moscati”, 83100 Avellino, Italy

Received 22 January 2015; Revised 4 April 2015; Accepted 20 April 2015

Academic Editor: Janaka Karalliedde

Copyright © 2015 Giuseppe Castaldo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Multiple weight loss failures among obese patients suggest the design of new therapeutic strategies. We investigated the role of 2-week course of enteral treatment with a very low-calorie protein-based formula in the management of severe obesity. Methods. We evaluated the feasibility, safety, and efficacy of 2-week continuous administration of a protein-based formula (1.2 g/kg of ideal body weight/day) by nasogastric tube in severely obese adults (body mass index (BMI) ≥ 40 kg/m2). Results. In total, 364 patients (59% women; BMI =  kg/m2) were recruited. The intervention was discontinued within 48 hours in 26 patients, due to nasogastric tube intolerance. No serious adverse events occurred. During the first and the second week, 65% and 80% patients, respectively, reported no side effects. All biochemical safety parameters were affected by the intervention, particularly uric acid (+45%) and aminotransferases (+48%). In the other cases the change was negligible. We observed significant weight loss (%) and improvement in blood pressure and glucose and lipid metabolism parameters (). Conclusions. A 2-week course of enteral treatment with a very low-calorie protein-based formula appeared a feasible, likely safe, and efficacious therapeutic option to be considered for inclusion into a composite weight loss program for the management of severe obesity. This trial is registered with ClinicalTrials.gov Identifier: NCT01965990.